4547 — Kissei Pharmaceutical Co Income Statement
0.000.00%
- ¥180bn
- ¥134bn
- ¥88bn
- 67
- 40
- 99
- 81
Annual income statement for Kissei Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
Standards: | JAS | JAS | JAS | JAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 69,044 | 65,381 | 67,493 | 75,579 | 88,330 |
Cost of Revenue | |||||
Gross Profit | 32,723 | 31,238 | 32,375 | 37,341 | 44,065 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 66,893 | 67,223 | 68,556 | 71,257 | 85,762 |
Operating Profit | 2,151 | -1,842 | -1,063 | 4,322 | 2,568 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 7,476 | 16,507 | 13,680 | 14,449 | 15,610 |
Provision for Income Taxes | |||||
Net Income After Taxes | 5,378 | 13,032 | 10,634 | 11,290 | 11,976 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 5,285 | 12,922 | 10,529 | 11,162 | 11,962 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 5,285 | 12,921 | 10,528 | 11,160 | 11,961 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 103 | 288 | 226 | 240 | 334 |
Dividends per Share |